Diligence memo · auto-generated · as of July 2, 2026

NeuroQore, Inc.

NeuroQore, Inc. looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

NeuroQore, Inc. operates in Biotechnology, based in MOUNTAIN VIEW.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

NeuroQore, Inc. has raised $1.5M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $1.5M on 2025-07-14.

Most recent recorded round closed around 2025-07-14.

Valuation (modeled)modeled

Provath models NeuroQore, Inc. at approximately $4.1M (range $1.1M–$8.3M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.91× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era. Within the normal band (91% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 12 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

Comparablesmixed

Capital scale ranks ahead of 24% of Biotechnology peers (4293 compared).

Modeled value ranks above 9% of those peers.

Closest niche peers: Carna Inc., NRX Pharmaceuticals, Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp..

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.